Clinical Study | Open Access
Sanjib Kumar Sharma, Emilie Alirol, Anup Ghimire, Suman Shrestha, Rupesh Jha, Surya B. Parajuli, Deekshya Shrestha, Surya Jyoti Shrestha, Amir Bista, David Warrell, Ulrich Kuch, Francois Chappuis, Walter Robert John Taylor, "Acute Severe Anaphylaxis in Nepali Patients with Neurotoxic Snakebite Envenoming Treated with the VINS Polyvalent Antivenom", Journal of Tropical Medicine, vol. 2019, Article ID 2689171, 12 pages, 2019. https://doi.org/10.1155/2019/2689171
Acute Severe Anaphylaxis in Nepali Patients with Neurotoxic Snakebite Envenoming Treated with the VINS Polyvalent Antivenom
Diagnosing and treating acute severe and recurrent antivenom-related anaphylaxis (ARA) is challenging and reported experience is limited. Herein, we describe our experience of severe ARA in patients with neurotoxic snakebite envenoming in Nepal. Patients were enrolled in a randomised, double-blind trial of high vs. low dose antivenom, given by intravenous (IV) push, followed by infusion. Training in ARA management emphasised stopping antivenom and giving intramuscular (IM) adrenaline, IV hydrocortisone, and IV chlorphenamine at the first sign/s of ARA. Later, IV adrenaline infusion (IVAI) was introduced for patients with antecedent ARA requiring additional antivenom infusions. Preantivenom subcutaneous adrenaline (SCAd) was introduced in the second study year (2012). Of 155 envenomed patients who received ≥ 1 antivenom dose, 13 (8.4%), three children (aged 5−11 years) and 10 adults (18−52 years), developed clinical features consistent with severe ARA, including six with overlapping signs of severe envenoming. Four and nine patients received low and high dose antivenom, respectively, and six had received SCAd. Principal signs of severe ARA were dyspnoea alone (n=5 patients), dyspnoea with wheezing (n=3), hypotension (n=3), shock (n=3), restlessness (n=3), respiratory/cardiorespiratory arrest (n=7), and early (n=1) and late laryngeal oedema (n=1); rash was associated with severe ARA in 10 patients. Four patients were given IVAI. Of the 8 (5.1%) deaths, three occurred in transit to hospital. Severe ARA was common and recurrent and had overlapping signs with severe neurotoxic envenoming. Optimising the management of ARA at different healthy system levels needs more research. This trial is registered with NCT01284855.
Snake antivenoms are the only specific treatments for snakebite envenoming; they save lives but are associated with acute pyrogenic reactions, due to endotoxin contamination whilst in production, and acute anaphylaxis .
The mechanisms underlying antivenom-related anaphylaxis (ARA) are uncertain and are probably a combination of complement activation, a type I hypersensitivity reaction, non-allergen-specific activation of mast cells triggered by the antivenom impurities and immune priming due to the venom itself [2, 3]; indeed, anaphylaxis has been reported in snake handlers after >1 envenoming . The reported rates of ARA range from <5 up to <90% depending on the quality of the antivenom used and the diligence in recording events [5–12]. One report from Thailand suggested higher rates in cobra-bitten (~12%) vs. viper-bitten (~2%) patients  whereas a larger Indian study found the opposite relationship .
ARA has the same clinical features as other causes of anaphylaxis. Common (20-50%) features include urticaria, tachycardia, hypotension, tachypnoea, dyspnoea, wheeze, and angioedema. Restlessness, agitation, confusion, laryngeal obstruction, stridor, sinus bradycardia, and relative bradycardia with hypotension are seen less frequently [8, 9, 15, 16].
Severe life-threatening ARA characterised by shock, hypoxia, and reduced consciousness/confusion were low (<2 – ~7%) in studies from Ecuador , Papua New Guinea , Australia , and India  but were ~22–33% in Sri Lanka [6, 10, 19], Bangladesh , Pakistan , and Laos . ARA is reduced substantially by administering subcutaneous adrenaline (SCAd) before antivenom is given .
Intramuscular adrenaline (IMAd) is the treatment of choice for acute ARA, but ARA may respond poorly (protracted anaphylaxis) or recur later (biphasic anaphylaxis) . Giving additional doses of antivenom to treat progressive or recurrent envenoming is another important cause of recurrent ARA . The optimal management of protracted or recurrent ARA is unclear. One recommendation is an intravenous adrenaline infusion (IVAI)  with tight control of the blood pressure to avoid adrenaline-induced toxicity like hypertension and intracranial haemorrhage .
Most venomous snake bites in Nepal are caused by spectacled and monocled cobras, Naja Naja and Naja kaouthia, and the common krait, Bungarus caeruleus . Their neurotoxic venoms cause death by paralysing the bulbar and respiratory muscles. Indian-manufactured, equine-derived, polyvalent antivenom raised against the venoms of B. caeruleus, Daboia russelii (Russell’s viper), Echis carinatus (saw-scaled viper), and N. naja is the only antivenom available in Nepal and, in one study, was associated with severe ARA in ~22% of recipients .
We reported previously the efficacy and tolerability of high vs. low dose antivenom in neurotoxic envenomed patients . Herein, we focus on severe ARA.
2.1. Study Design and Site
Study details are published elsewhere . Briefly, this double-blind, placebo-controlled trial took place from April 2011 to March 2013 at Bharatpur Hospital, a tertiary referral hospital with an intensive care unit (ICU), Bharatpur, and two snakebite treatment centres: (i) Snake Bite Treatment Centre, Nepal Red Cross Society, Damak, and (ii) Snake Bite Management Centre, Charali, which are 60 km (1.5 h) and 100 km (2.5 h), respectively, from the B.P. Koirala Institute of Health Sciences (BPKIHS), a university hospital with an ICU. Transferred patients to BPKIHS were accompanied by a doctor. Data analysis in this short report was descriptive.
Ethical clearance was obtained from the B.P. Koirala Institute of Health Sciences Ethics Committee (approval n°ACA-575-/067/068), the Nepal Health Research Council (approval n°986), and the Geneva University Hospitals Ethics Committee (approval n°08-192). All study participants gave written informed consent to participate in this study.
2.2. Inclusion/Exclusion Criteria
Recruited patients were aged ≥ 5 years (y), with signs of neurotoxic envenoming, assessed using a neurotoxicity score (NS, Box 1), who/whose guardians gave signed, informed consent. Excluding criteria were (i) pregnant or breast feeding women, (ii) presentation > 24 h, (iii) patients needing immediate mechanical ventilation [respiratory distress, no gag reflex, paradoxical breathing and/or oxygen saturation (SpO2)] < 90% on room air], (iv) known allergy to horse proteins, (v) patients (a) with an underlying neuromuscular disease, (b) with a proven viper bite, and (c) who had received antivenom earlier at another health centre.
2.3. Antivenom Dose and Adjunct Treatments
We used the VINS manufactured polyvalent antivenom (VINS Bio-pharmaceuticals Corp. Ltd., Mumbai, India); all antivenom came from one batch: #01AS11004. This antivenom contains horse derived F(ab')2 antibody fragments against B. caeruleus, D. russelii, E. carinatus, and N. naja from India and is associated with severe ARA rates ranging from 4  − 21% .
Patients were randomised to either the Nepali recommended low dose (LD) regimen: 6 vials, 2 by IV push over 5-10 m, then 4 infused over 4 h (1h & 3h infusions), or high dose (HD) antivenom: 10 vials by IV push over 5-10 m, then 8 vials infused over 1 h and 3 h normal saline infusion to maintain the blind. Persisting neurotoxic signs were treated with 4h infusions of 4 vials (LD arm) or saline (HD arm). Acute neurological deterioration (i.e., increased NS) was treated with 2 vials (LD arm) or 5 vials (HD arm) by IV push.
All patients received neostigmine to enhance neuromuscular transmission  and atropine to prevent the muscarinic effects of neostigmine (hypersalivation, colic, pulmonary oedema, and sinus bradycardia).
2.4. Patient Monitoring
Patients were monitored hourly until the NS became 0 (i.e., complete resolution of neurotoxic signs) then 6 hourly and included emergent symptoms and signs, vital signs, NS, and SpO2 measured by finger oximeter [MD300D (adults), MD 300C5 (children), Vandagraph, United Kingdom]. Patients were followed up on days 7 and 21 and at 6 months.
2.5. Reporting of Severe Anaphylaxis
Severe acute anaphylaxis meets the definition of a serious adverse event (SAE), i.e., life-threatening, prolongs inpatient stay, or results in death . All clinical details were recorded on SAE forms by the site investigator under the supervision of the study site principal investigator (SKS) who was on call 24 h/day. All SAE reports were reviewed by EA, FC, & WRJT and then sent to the ethics committees of the BPKIHS and Geneva University Hospitals, the Nepal Health Research Council (NHRC) and the Drug Safety and Monitoring Board (DSMB) for comments.
For this report, the senior author reviewed again all SAE forms and associated communications to reconstruct the clinical picture from patient admission to discharge or death. Clinical events, defined as important symptoms or signs, were identified and the following details were recorded: (i) their timing, (ii) how often they occurred, (iii) what their causes were, (iv) how and at what times they were treated, and (v) outcomes. Data were entered into Microsoft Excel and analysed [descriptive analyses and Mann–Whitney U test (continuous data)] in Stata v14 (Stata Corporation, USA).
2.6. Prevention of Anaphylaxis
Premedication with SCAd was given in the second snakebite season in 2012 following the report by de Silva et al. . The dose was 0.25 mL (patients aged ≥ 13 y), 0.2 mL (11-12 y) and 0.125 mL (5-10 y) of a 1:1,000 solution of adrenaline.
2.7. Definition and Treatment of Anaphylaxis
We used the definition recommended by the National Institute of Allergy and Infectious Disease and Food Allergy and Anaphylaxis Network, “anaphylaxis is a serious allergic reaction that is rapid in onset and may cause death” .
All clinical teams received prestudy and refresher trainings in the recognition and treatment of anaphylaxis, including (i) a list of key symptoms and signs (itching, urticaria, swollen lips or tongue, angioedema, dry cough, wheezing, stridor, hoarse voice, ‘lump in throat’, nausea, vomiting, abdominal colic, diarrhoea, hypotension, and shock), (ii) ABC of resuscitation (airway: obstruction/compromise, breathing: tachypnoea, wheezing, and circulation: hypotension or shock +/- poor peripheral circulation), (iii) intubation and the use of an Ambu bag. We stressed the urgency of treating anaphylaxis when the first sign/s consistent with ARA appeared, irrespective of their severity , which consisted of IMAd, IV hydrocortisone, and IV chlorphenamine, following international guidelines [30–32]. Training did not include performing a cricothyrotomy or a tracheotomy.
For patients who had experienced ARA but needed more antivenom to treat envenoming, antivenom infusions were resumed when patients were either haemodynamically stable or when the treating physician thought the anaphylaxis was clinically resolved. A reappearance of ARA was treated as above, but we later replaced this practice with IVAIs to “cover” additional doses of antivenom infusion, following the regimen of Brown et al. . IVAIs were adopted because (i) it was sometimes difficult to decide when ARA had resolved fully and so whether it was “safe” to restart the antivenom infusion and (ii) to prevent multiple injections of IMAd if physicians thought patients were having ongoing ARA during the antivenom infusions. Antivenom pushes (as above) for acute neurological deterioration were not covered by adrenaline.
3.1. Demographic and ARA Summary Data
155 patients with neurotoxic envenoming received at least one dose of antivenom and are included in this analysis, including one patient who later withdrew from the study (Figure 1).
In total, 13 [8.4%, 95% confidence interval (CI) 4.9-13.8%] patients had severe ARA, three were children aged 5, 6, and 11 y and 10 adults, aged 18–52 y (Table 1). Snake identification, by an expert herpetologist or polymerase chain reaction of bite swabs, was possible in six patients.
Over time, these 13 patients had 64 clinical events: two patients had 3 events, six had 4 events, two had 5 events, and three had 8 events (Table 2). Some events led rapidly to a cascade of additional events whilst others were separated by large time periods (Figure 2).
NS D0: neurotoxicity score on Day 0 (baseline); AVR: antivenom regimen; H: high-dose antivenom regimen; L: low-dose antivenom regimen; CR: cardiorespiratory; SB: sinus bradycardia.
P Resp: paradoxical respiration; LO: laryngeal oedema; VAP: ventilator associated pneumonia; D: died; R: resolved.
: unilateral lower eyelid swelling.
: recorded as angioedema, exact anatomical location unknown.
Median (range) times to the first clinical symptom or sign consistent with ARA after the most recent dose of antivenom were (i) 19 (5-115) minutes (m) after the first IV push of antivenom, (ii) 52.5 (11-155) m (second dose), and (iii) 75 (30-770) m (third dose). SCAd was given to 6 patients in 2012 and four and nine patients received LD and HD antivenom, respectively, but the times to the first ARA event were not significantly different between (i) SCAd recipients 17 (5-40) m vs. nonrecipients 30 m (p=0.5) and (ii) LD 14.5 (5-40) m vs. HD 28 (5-115) m regimens (p=0.4).
There were 8 deaths (#s 6–13, Table 3), for a case fatality rate of 5.16 (2.25 – 9.9)%. Five occurred in Bharatpur Hospital. The median time to death was 3.5 h [IQR 1.6–18.4 h (range 1.3 h–11 d). None of the patients who died had acute features of a cholinergic crisis.
: time from the start of the intravenous push (T0) to the time death was certified. SCAd, subcutaneous adrenaline, IMAd: intramuscular adrenaline, SC: subcutaneous, IV: intravenous, IM: intramuscular.
h: hour, m: minute, y: years, NS: neurotoxicity score, AV: antivenom, AVI: antivenom infusion, ET: endotracheal tube, SpO2: oxygen saturation, ARA: antivenom related anaphylaxis.
3.2. ARA Clinical Features & Management
The clinical features were similar between the LD and HD patients (Table 2). Rash, documented as urticaria, erythema, or ‘itchy rashes’ were the most common ARA manifestation and occurred during the first ARA episode in 10 patients (Tables 2, 3, and 4). Five patients had other concomitant signs of ARA whilst the other five all went on to develop other features of ARA over time. Severe ARA signs included dyspnoea alone or with wheezing, hypotension, shock, restlessness, and respiratory or cardiorespiratory arrest; two patients with dyspnoea manifested as gasping respirations (#8, #12). Early (#1) and late (#11) laryngeal oedema (E & LLO) were seen in two patients. The ELO occurred 35m into the resumption of his first antivenom infusion (interrupted because of an itchy rash), corresponding to 95 m after the IV push; clinical signs were noisy breathing, cough, and a fall in SpO2 to 63%. The patient with LLO developed a hoarse voice 8 h 35 m after his antivenom infusion had finished (11h after IV push). Stridor was not a feature of either E or LLO.
SCAd: subcutaneous adrenaline, IMAd: intramuscular adrenaline, SC: subcutaneous, IV: intravenous, IM: intramuscular, h: hour, m: minute, y: years, NS: neurotoxicity score.
AV: antivenom, SpO2: oxygen saturation, ARA: antivenom related anaphylaxis.
In most ARA-diagnosed patients, antivenom was stopped and IMAd given almost immediately after the ARAs were recognised (Figure 1), followed by IV hydrocortisone and IV chlorphenamine. Nebulisers were given to one patient (#8) without IMAd who continued to receive antivenom without deterioration. Two patients (#s5 & 10) received IMAd after IV hydrocortisone at 6 and 15 m after the start of their first ARAs without deleterious effects. One and three patients were given IV adrenaline and SCAd, respectively, instead of IMAd. Four patients (#s1, 3, 10, 12) were admitted to Bharatpur Hospital and treated with five adrenaline infusions so antivenom could be restarted following antecedent reactions: (i) patient 1: initial antivenom induced rash had resolved, (ii) patient 3: it was unclear if the initial episode of severe ARA had resolved; the patient was ventilated and needed additional antivenom, (iii) patient 10: the patient had partial resolution of antivenom induced rash, and (iv) patient 12: despite two injections of IMAd, patient’s rash remained unresolved; IVAI was used to complete the initial IV push of antivenom.
3.3. Deaths in Patients with Indeterminate Clinical Features
Six patients (#s 6, 7, 8, 9, 12, 13) had events with clinical features consistent with severe ARA and severe neurotoxic envenoming, although they were all considered to be antivenom-related at the time by the treating physicians (Table 3). Patient 7, whose presentation included dyspnoea, suffered a respiratory arrest and sinus bradycardia 15 m after starting antivenom; despite IMAd, intubation and oxygen, she had a cardiac arrest and died in the ambulance on the way to hospital. The other five patients had increasing neurotoxic scores (n=4), sudden cardiac arrest (n=1), dyspnoea without wheeze (n=1), gasping respiration (n=1), falling oxygen saturation (n=4), restlessness (n=2), hypotension (n=1), and sinus bradycardia (n=4, 5 episodes) that was followed rapidly by death. At the time of these clinical events, patient 9 was on an antivenom infusion, three had received IV push injections for neurological deterioration, and one was under observation in the ICU.
3.4. Other Deaths
One patient died of LLO (#11) and the other of anaphylactic shock (#10). Both patients died in the ambulance during hospital transfer.
Our study has documented a relatively high rate (~8%) of VINS antivenom associated ARA that was clinically clear-cut in seven patients but clouded in six mostly by a mix of dyspnoea, restlessness, and increasing neurological scores, all consistent with envenoming.
Acute anaphylaxis is a predictable toxicity of antivenom. The Indian-manufactured antivenoms, used commonly in south Asian countries, are associated with rates of severe ARA as high as ~20 to 40% [3, 6, 10, 19]. Recurrent ARA may recur acutely when additional doses of antivenom are given as infusions or IV pushes and “unexpectedly” as biphasic anaphylaxis hours after the apparent resolution of antecedent episode of ARA [9, 21]. Moreover, patients may “unexpectedly” deteriorate clinically because of a recrudescence of their envenoming despite an initially good clinical response to antivenom. We faced such challenges in several patients.
The most difficult patients were those who developed restlessness and/or acute dyspnoea/gasping respiration with (e.g., #s13, 8) or without (e.g., #12, 9) an increase in the NS score and patients who deteriorated rapidly, culminating in a cardiac/respiratory arrest, whether they were treated for ARA (#6) or not (#7). Sinus bradycardia was an ominous sign that preceded cardiac arrest and death. With an acute increase in NS, clinicians may believe the acute clinical deterioration is exclusively due to worsening envenoming. However, they should consider whether an earlier antivenom infusion or IV push is contributing either acutely or as biphasic ARA and should have a low threshold for treating with IMAd.
To increase clinical awareness, we suggest several “danger” signs that require urgent assessment such as sinus bradycardia, relative bradycardia and hypotension , dyspnoea alone or with wheezing, hoarse voice, restlessness, and nonspecific acute clinical deterioration. These signs may occur in isolation or within a picture of worsening neurotoxicity that may be confusing and lead clinicians not to consider ARA.
Five patients developed dyspnoea without wheezing; two (one as gasping respiration) did not have a concomitant decline in NS whilst one gasping patient did. Although wheeze is a classic sign of acute anaphylaxis, dyspnoea alone is well documented and was more common than wheeze in two large clinical series. In one ARA study, ~16% (32/198) patients developed hypoxia, 3% wheeze and hypoxia and 3.5% wheeze alone  and, in a study of all cause anaphylaxis (n=1,149), dyspnoea alone was present in 29% patients vs. 13% who had wheeze . Acute dyspnoea without wheezing is also a well-characterised feature of progressive neurotoxic envenoming (leading to insufficient respiratory muscle strength and increasing NS) which requires rapid treatment with antivenom +/- assisted ventilation. Moreover, dyspnoea should always prompt the exclusion of mechanical blockage of the airway (e.g., a prolapsed tongue), and faulty intubation (e.g., into one bronchus) in ventilated patients.
Two patients developed laryngeal oedema neither of whom had stridor. The LLO patient had recovered from his earlier mild ARA and envenoming and his hoarse voice developed 8.5 h postantivenom infusion. It is unclear whether LO developed late and progressed rapidly (i.e., biphasic anaphylaxis) or insidiously to become clinically manifest only when the oedema was severe. He was unresponsive to adrenaline and hydrocortisone and the extent of the LO precluded endotracheal intubation. Without surgical equipment and skilled staff to relieve his upper airway obstruction (UAO), he died. The risk of laryngeal obstruction/oedema/stridor/throat tightness was 2% (1/48) in snakebite victims in Australia .
UAO is classed as both moderately severe  and life-threatening . In settings where intubation is problematic, mechanical ventilators are several hours away, and death during hospital transfer is well described , UAO is better classed as life-threatening. In retrospect, had we anticipated that LO might prevent intubation, we would have added training on cricothyrotomy/tracheotomy together with the necessary equipment.
During the study, our guidelines on treating recurrent ARA changed from treating each episode with IMAd to IVI to cover subsequent antivenom infusions . Four patients, all enrolled at Bharatpur Hospital, received adrenaline infusions. Given the potential dangers of IVAI (e.g., cardiac arrhythmias, acute hypertension, and haemorrhagic stroke), the need for close monitoring, e.g., 3−5 m  and infusion titration, IVAIs are suitable only where there are well-trained ICU or emergency staff. More research is needed to optimise the management of patients with antecedent ARA who require repeated antivenom infusions or IV antivenom pushes for acute neurological deterioration.
We had a crude fatality rate (CFR) of ~5%, higher than the 1.3% reported by de Silva et al. in their large (n=1007) trial that was conducted in hospitals with experience of snakebite management  but lower than the 13  to 20%, with marked interclinic variation , reported previously in Nepal. Nevertheless, these data support a relationship of limited resources and skills and higher CFRs.
To conclude, we have highlighted the risks of severe ARA in neurotoxic envenomed patients and challenges in managing patients where resources are limited. Clinicians should have a low threshold for treating of ARA when the clinical picture is not clear-cut and ARA cannot be excluded. More research is needed to define optimal treatment strategies in different health settings, especially snakebite centres.
The data that are presented in this anaphylaxis paper are available in Microsoft XL. All data requests should be addressed to Professor F. Chappuis: Francois.Chappuis@hcuge.ch.
Conflicts of Interest
No author has conflicts of interest.
Walter Robert John Taylor extracted and analysed the key data and wrote the first draft of the paper. Professors Francois Chappuis and Sanjib Kumar Sharma were the study and site PIs, respectively. Sanjib Kumar Sharma, Francois Chappuis, Emilie Alirol, Anup Ghimire, David Warrell, and Ulrich Kuch critically reviewed the manuscript. Sanjib Kumar Sharma, Anup Ghimire, Suman Shrestha, Rupesh Jha, Surya B. Parajuli, Deekshya Shrestha, Surya Jyoti Shrestha, and Amir Bista provided clinical care and collected the data. Emilie Alirol and Walter Robert John Taylor monitored the trial. Francois Chappuis, Sanjib Kumar Sharma, Emilie Alirol, and Ulrich Kuch designed the study with input from David Warrell and Walter Robert John Taylor.
We thank the patients and their guardians for enrolling into this study and the members of the DSMB: Professors J. White (chair), M. Boelaert, J. Desmeules, N. Jha, and P. B. Kshetry. James Watson of the Mahidol Oxford Tropical Medicine Research Unit kindly constructed Figure 1. The study was funded by the Swiss National Science Foundation, which had no role in study design, data collection, analysis, and interpretation, or in writing of the report.
- Antivenom Therapy and Reactions, “The Lancet,” vol. 315, no. 8176, pp. 1009-1010, 1980.
- R. D. G. Theakston and D. C. Smith, “Antivenoms,” BioDrugs, vol. 7, no. 5, pp. 366–375, 1997.
- S. F. Stone, G. K. Isbister, S. Shahmy et al., “Immune response to snake envenoming and treatment with antivenom; complement activation, cytokine production and mast cell degranulation,” PLOS Neglected Tropical Diseases, vol. 7, no. 7, p. e2326, 2013.
- S. A. De Nishioka, P. V. P. Silveira, F. M. Peixoto-Filho, M. T. Jorge, and A. Sandoz, “Occupational injuries with captive lance-headed vipers (Bothrops moojeni): Experience from a snake farm in Brazil,” Tropical Medicine & International Health, vol. 5, no. 7, pp. 507–509, 2000.
- S. R. Offerman, T. S. Smith, and R. W. Derlet, “Does the aggressive use of polyvalent antivenin for rattlesnake bites result in serious acute side effects?” Western Journal of Medicine, vol. 175, no. 2, pp. 88–91, 2001.
- H. A. de Silva, A. Pathmeswaran, C. D. Ranasinha et al., “Low-dose adrenaline, promethazine, and hydrocortisone in the prevention of acute adverse reactions to antivenom following snakebite: a randomised, double-blind, placebo-controlled trial,” PLoS Medicine, vol. 8, no. 5, p. e1000435, 2011.
- H. W. Fan, L. F. Marcopito, J. L. C. Cardoso et al., “Sequential randomised and double blind trial of promethazine prophylaxis against early anaphylactic reactions to antivenom for bothrops snake bites,” British Medical Journal, vol. 318, no. 7196, pp. 1451–1453, 1999.
- D. J. Williams, S. D. Jensen, B. Nimorakiotakis, R. Müller, and K. D. Winkel, “Antivenom use, premedication and early adverse reactions in the management of snake bites in rural Papua New Guinea,” Toxicon, vol. 49, no. 6, pp. 780–792, 2007.
- N. F. Moran, W. J. Newman, R. G. Theakston, D. A. Warrell, and D. Wilkinson, “High incidence of early anaphylactoid reaction to SAIMR polyvalent snake antivenom,” Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 92, no. 1, pp. 69-70, 1998.
- G. K. Isbister, S. Shahmy, F. Mohamed et al., “A randomised controlled trial of two infusion rates to decrease reactions to antivenom,” PLoS ONE, vol. 7, no. 6, p. e38739, 2012.
- M. A. Faiz, M. F. Ahsan, A. Ghose et al., “Bites by the Monocled Cobra, Naja kaouthia, in Chittagong Division, Bangladesh: Epidemiology, Clinical Features of Envenoming and Management of 70 Identified Cases,” The American Journal of Tropical Medicine and Hygiene, vol. 96, no. 4, pp. 876–884, 2017.
- J. L. Cardoso, H. W. Fan, F. O. França et al. et al., “Randomized comparative trial of three antivenoms in the treatment of envenoming by lance-headed vipers (Bothrops jararaca) in São Paulo, Brazil,” QJM: An International Journal of Medicine, vol. 86, no. 5, pp. 315–325, 1993.
- A. Thiansookon and P. Rojnuckarin, “Low incidence of early reactions to horse-derived F(ab′)2 antivenom for snakebites in Thailand,” Acta Tropica, vol. 105, no. 2, pp. 203–205, 2008.
- R. P. Deshpande, V. M. Motghare, S. L. Padwal et al., “Adverse drug reaction profile of anti-snake venom in a rural tertiary care teaching hospital,” Journal of Young Pharmacists, vol. 5, no. 2, pp. 41–45, 2013.
- G. K. Isbister, S. G. Brown, E. MacDonald, J. White, B. J. Currie, and Australian Snakebite Project Investigators, “Current use of Australian snake antivenoms and frequency of immediate-type hypersensitivity reactions and anaphylaxis,” The Medical Journal of Australia, vol. 188, no. 8, pp. 473–476, 2008.
- S. G. A. Brown, K. E. Blackman, V. Stenlake, and R. J. Heddle, “Insect sting anaphylaxis; prospective evaluation of treatment with intravenous adrenaline and volume resuscitation,” Emergency Medicine Journal, vol. 21, no. 2, pp. 149–154, 2004.
- R. Smalligan, J. Cole, N. Brito et al., “Crotaline snake bite in the Ecuadorian Amazon: Randomised double blind comparative trial of three South American polyspecific antivenoms,” British Medical Journal, vol. 329, no. 7475, pp. 1129–1133, 2004.
- S. Raina, S. Raina, R. Kaul, V. Chander, and A. Jaryal, “Snakebite profile from a medical college in rural setting in the hills of Himachal Pradesh, India,” Indian Journal of Critical Care Medicine, vol. 18, no. 3, pp. 134–138, 2014.
- G. K. Isbister, S. Jayamanne, F. Mohamed et al., “A randomized controlled trial of fresh frozen plasma for coagulopathy in Russell's viper (Daboia russelii) envenoming,” Journal of Thrombosis and Haemostasis, vol. 15, no. 4, pp. 645–654, 2017.
- J. Zafar, S. Aziz, B. Hamid, A. Qayyum, M. T. Alam, and R. A. Qazi, “Snake bite experience at Pakistan Institute of Medical Sciences,” The Journal of the Pakistan Medical Association, vol. 48, no. 10, pp. 308–310, 1998.
- I. Vongphoumy, P. Chanthilat, P. Vilayvong, and J. Blessmann, “Prospective, consecutive case series of 158 snakebite patients treated at Savannakhet provincial hospital, Lao People's Democratic Republic with high incidence of anaphylactic shock to horse derived F(ab')2 antivenom,” Toxicon, vol. 117, pp. 13–21, 2016.
- S. G. Brown, R. J. Mullins, and M. S. Gold, “Anaphylaxis: diagnosis and management,” The Medical Journal of Australia, vol. 185, no. 5, pp. 283–289, 2006.
- J. T. Levis, J. B. Ford, and A. M. Kuo, “Intracranial hemorrhage after prehospital administration of intramuscular epinephrine,” The Journal of Emergency Medicine, vol. 40, no. 6, pp. e107–e110, 2011.
- S. K. Sharma, U. Kuch, P. Höde et al., “Use of molecular diagnostic tools for the identification of species responsible for snakebite in nepal: a pilot study,” PLOS Neglected Tropical Diseases, vol. 10, no. 4, Article ID e0004620, 2016.
- E. Alirol, S. K. Sharma, A. Ghimire et al., “Dose of antivenom for the treatment of snakebite with neurotoxic envenoming: Evidence from a randomised controlled trial in Nepal,” PLOS Neglected Tropical Diseases, vol. 11, no. 5, p. e0005612, 2017.
- I. B. Gawarammana, S. A. M. Kularatne, R. P. V. Kumarasiri, N. Senanayake, W. P. Dissanayake, and H. Ariyasena, “Parallel infusion of hydrocortisone +/- chlorpheniramine bolus injection to prevent acute adverse reactions to antivenom for snakebites,” Medical Journal of Australia, vol. 180, no. 1, pp. 20–23, 2004.
- Watt G., B. D. Meade, R. D. Theakston et al., “Comparison of Tensilon and antivenom for the treatment of cobra-bite paralysis,” Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 83, no. 4, pp. 570–573, 1989.
- I. R. Edwards and J. K. Aronson, “Adverse drug reactions: definitions, diagnosis, and management,” The Lancet, vol. 356, no. 9237, pp. 1255–1259, 2000.
- H. A. Sampson, A. Muñoz-Furlong, R. L. Campbell et al., “Second symposium on the definition and management of anaphylaxis: summary report—second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium,” Annals of Emergency Medicine, vol. 47, no. 4, pp. 373–380, 2006.
- D. A. Warrell and C. Arnett, “The importance of bites by the saw scaled or carpet viper (Echis carinatus): epidemiological studies in Nigeria and a review of the world,” Acta Tropica, vol. 33, no. 4, pp. 307–341, 1976.
- J. Soar, “Emergency treatment of anaphylaxis in adults: concise guidance,” Clinical Medicine, vol. 9, no. 2, pp. 181–185, 2009.
- Y. Tse and G. Rylance, “Emergency management of anaphylaxis in children and young people: new guidance from the Resuscitation Council (UK),” ADC - Education and Practice Edition, vol. 94, no. 4, pp. 97–101, 2009.
- P. Y. Gueugniaud, E. Peverelli, T. Vaudelin, C. Choux, and P. Petit, “Relative bradycardia in anaphylactoid shock,” Presse medicale (Paris, France : 1983), vol. 18, no. 14, p. 726, 1989.
- S. G. A. Brown, “Clinical features and severity grading of anaphylaxis,” The Journal of Allergy and Clinical Immunology, vol. 114, no. 2, pp. 371–376, 2004.
- H. S. Bawaskar and P. H. Bawaskar, “Profile of snakebite envenoming in Western Maharashtra, India,” Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 96, no. 1, pp. 79–84, 2002.
- G. K. Isbister, S. G. Brown, C. B. Page, D. L. McCoubrie, S. L. Greene, and N. A. Buckley, “Snakebite in Australia: a practical approach to diagnosis and treatment,” Medical Journal of Australia, vol. 199, no. 11, pp. 763–768, 2013.
- C. T. Magar, K. Devkota, R. Gupta, R. K. Shrestha, S. K. Sharma, and D. P. Pandey, “A hospital based epidemiological study of snakebite in western development region, Nepal,” Toxicon, vol. 69, pp. 98–102, 2013.
- S. K. Sharma, B. Khanal, P. Pokhrel, A. Khan, and S. Koirala, “Snakebite-reappraisal of the situation in Eastern Nepal,” Toxicon, vol. 41, no. 3, pp. 285–289, 2003.
Copyright © 2019 Sanjib Kumar Sharma et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.